» Articles » PMID: 28902142

Blood-Brain Barrier Dysfunction and the Pathogenesis of Alzheimer's Disease

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2017 Sep 14
PMID 28902142
Citations 178
Authors
Affiliations
Soon will be listed here.
Abstract

Brain capillary endothelial cells form the blood-brain barrier (BBB), which is covered with basement membranes and is also surrounded by pericytes and astrocyte end-feet in the neurovascular unit. The BBB tightly regulates the molecular exchange between the blood flow and brain parenchyma, thereby regulating the homeostasis of the central nervous system (CNS). Thus, dysfunction of the BBB is likely involved in the pathogenesis of several neurological diseases, including Alzheimer's disease (AD). While amyloid-β (Aβ) deposition and neurofibrillary tangle formation in the brain are central pathological hallmarks in AD, cerebrovascular lesions and BBB alteration have also been shown to frequently coexist. Although further clinical studies should clarify whether BBB disruption is a specific feature of AD pathogenesis, increasing evidence indicates that each component of the neurovascular unit is significantly affected in the presence of AD-related pathologies in animal models and human patients. Conversely, since some portions of Aβ are eliminated along the neurovascular unit and across the BBB, disturbing the pathways may result in exacerbated Aβ accumulation in the brain. Thus, current evidence suggests that BBB dysfunction may causatively and consequently contribute to AD pathogenesis, forming a vicious cycle between brain Aβ accumulation and neurovascular unit impairments during disease progression.

Citing Articles

Endothelial progenitor cells and cerebral small vessel disease in carriers.

Kapoor A, Dutt S, Nguyen A, Lohman T, Gaubert A, Alitin J Cereb Circ Cogn Behav. 2025; 8:100378.

PMID: 40034682 PMC: 11872604. DOI: 10.1016/j.cccb.2025.100378.


Target the Heart: a new axis of Alzheimer's disease prevention.

Heller L, Lowe A, Del Rosario Hernandez T, Gore S, Chatterjee M, Creton R bioRxiv. 2025; .

PMID: 39975163 PMC: 11838187. DOI: 10.1101/2025.01.27.634057.


Peripheral proteinopathy in neurodegenerative diseases.

Xu B, Lei X, Yang Y, Yu J, Chen J, Xu Z Transl Neurodegener. 2025; 14(1):2.

PMID: 39819742 PMC: 11737199. DOI: 10.1186/s40035-024-00461-6.


Unveiling biomarker detection in Alzheimer's disease: a computational approach to microarray analysis.

Khan N, Choudhary S, Ali M, Shawaz M, Lohnes B, Poddar N 3 Biotech. 2024; 14(12):311.

PMID: 39606011 PMC: 11589038. DOI: 10.1007/s13205-024-04159-4.


Molecular Mechanisms Underlying Amyloid Beta Peptide Mediated Upregulation of Vascular Cell Adhesion Molecule-1 in Alzheimer Disease.

Salian V, Tang X, Thompson K, Curan G, Lowe V, Li L J Pharmacol Exp Ther. 2024; 391(3):430-440.

PMID: 39455283 PMC: 11585316. DOI: 10.1124/jpet.124.002280.


References
1.
Dysken M, Nelson M, Hoover K, Kuskowski M, McGeachie R . Rapid dynamic CT scanning in primary degenerative dementia and age-matched controls. Biol Psychiatry. 1990; 28(5):425-34. DOI: 10.1016/0006-3223(90)90410-4. View

2.
Algotsson A, Winblad B . The integrity of the blood-brain barrier in Alzheimer's disease. Acta Neurol Scand. 2007; 115(6):403-8. DOI: 10.1111/j.1600-0404.2007.00823.x. View

3.
Haydon P, Carmignoto G . Astrocyte control of synaptic transmission and neurovascular coupling. Physiol Rev. 2006; 86(3):1009-31. DOI: 10.1152/physrev.00049.2005. View

4.
Heneka M, Carson M, El Khoury J, Landreth G, Brosseron F, Feinstein D . Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015; 14(4):388-405. PMC: 5909703. DOI: 10.1016/S1474-4422(15)70016-5. View

5.
Yarchoan M, Xie S, Kling M, Toledo J, Wolk D, Lee E . Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias. Brain. 2012; 135(Pt 12):3749-56. PMC: 3577102. DOI: 10.1093/brain/aws271. View